@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech
@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce
@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce
> Not everyone in biotechnology is finding fame and fortune on Wall Street. Gene therapy player BioCardia failed to float its IPO, deciding to postpone the offering to a later date. Story
> San Diego-based Dauntless Pharmaceuticals has launched with a $12 million round backed by CEO Joel Martin and Sofinnova. The money will be used to advance DP1038, a preclinical-stage drug for endocrine cancers. Release
> The UK's Oxford Nanopore Technologies raised $109 million. Release
Medical Device News
@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev
@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce
> iHealth expands its retail, connected medical device empire and looks to move into corporations, hospitals. Article
> Propeller Health receives FDA clearance to sell its app and sensor to patients using Glaxo's inhalers. More
> Bloomberg: St. Jude Medical discussing takeover of Thoratec. Report
Pharma News
@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce
> Drugmakers like Gilead, Mylan and Novo, not Big Pharma, are job creators. More
> Should J&J break up? Get ready for a new round of debate. Story
Biotech Research News
> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report
> Animal study highlights role of mast cells in chronic eye diseases. More
> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report
> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story
> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article
Diagnostics News
> Illumina launches new lab service for HiSeq X sequencing systems. More
> Alere revs up engine with new deals and win for quick strep test. Story
> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News
> Oxford Nanopore reels in $109M to ramp up R&D. Item
> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article
Pharma Marketing News
> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More
> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item
> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report
> What's in a pill color? Consumers see messages in red, blue, green and white. Story
> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article